Coxsackievirus B4 expression vectors and uses thereof

Details Coxsackievirus B4 expression vectors and uses thereof Coxsackievirus B4 expression vectors and uses thereof

2007-09-18

2007-09-18

Chen, Stacy B. (Department: 1648)

Chemistry: molecular biology and microbiology

Vector, per se

C536S023100

Reexamination Certificate

active

09879572

ABSTRACT:
Disclosed is a recombinant attenuated coxsackievirus B4 virion which is engineered to contain a heterologous nucleic acid within the open reading frame of its genome, wherein the heterologous nucleic acid encodes a heterologous polypeptide which is expressed by the virion. Specific examples of attenuated coxsackievirus B4 virions suitable for use in the present invention are CB4-P and JVB. In one embodiment the heterologous nucleic acid is inserted into the P1 region of the genome such that the heterologous polypeptide is expressed as a fusion of a viral capsid protein. Methods of use of the recombinant attenuated coxsackievirus B4 virion include inducing an immune response in an individual to the heterologous polypeptide contained therein.

REFERENCES:
patent: 6323024 (2001-11-01), Tracy et al.
patent: WO98/39426 (1998-09-01), None
Saag et al., “HIV-1 and HAART: A Time to Cure, a Time to Kill,” Nature Medicine, Jun. 1999, vol. 5, No. 6, pp. 609-611.
Gotch et al., “Therapeutic Vaccines in HIV.1 Infection,” Immunological Reviews, 1999, vol. 170, pp. 173-182.
Rueckert, R. R., “Picornaviridae: The Viruses and Their Replication,”Fundamental Virology, 3rd ed. Philadelphia: Lippincott-Raven, 1996, Chapter 16, pp. 477-522.
Melnick, J. L., “Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses, and Newer Enteroviruses,”Fields Virology. In: Fields, B. N., Knipe, D. M., Howley, P. M., et al. editors. 3rd ed. Philadelphia: Lippincott—Raven Publishers, 1996, Chapter 22, pp. 655-712.
Jenkins et al., “The Complete Nucleotide Sequence of Coxsackievirus B4 and Its Comparison to Other Members of the Picornaviridae,” Journal of General Virology, 1987, vol. 68, pp. 1835-1848.
Halim et al., “A Point Mutation in VP1 of Coxsackievirus B4 Alters Antigenicity,” Virology, 2000, vol. 269, pp. 86-94.
Dedieu et al., “Poliovirus Chimeras Expressing Sequences from the Principal Neutralization Domain of Human Immunodeficiency Virus Type I,” Journal of Virology, May 1992, vol. 66, No. 5, pp. 3161-3167.
Evans et al., “An Engineered Poliovirus Chimaera Elicits Broadly Reactive HIV-1 Neutralizing Antibodies,” Nature, Jun. 1989, vol. 339, pp. 385-388.
Jenkins et al., “An Antigen Chimera of Poliovirus Induces Antibodies Against Human Papillomavirus Type 16,” Journal of Virology, Mar. 1990, vol. 64, pp. 1201-1206.
Murdin et al., “A Poliovirus Hybrid Expressing a Neutralization Epitope from the Major Outer Membrane Protein ofChlamydia trachomatisis Highly Immunogenic,” Infection and Immunity, Oct. 1993, vol. 61, No. 10, pp. 4406-4414.
Lu et al., “Construction and Genetic Analysis of Dicistronic Polioviruses Containing Open Reading Frames for Epitopes of Human Immunodeficiency Virus Type 1 gp120,” Journal of Virology, Aug. 1995, vol. 69, No. 8, pp. 4797-4806.
Andino et al., “Engineering Poliovirus as a Vaccine Vector for the Expression of Diverse Antigens,” Science, Sep. 1994, vol. 265, pp. 1448-1451.
Mueller et al., “Expression of Foreign Proteins by Poliovirus Polyprotein Fusion: Analysis of Genetic Stability Reveals Rapid Deletions and Formation of Cardioviruslike Open Reading Frames,” Journal of Virology, Jan. 1998, vol. 72, No. 1, pp. 20-31.
Tang et al., “Toward a Poliovirus-Based Simian Immunodeficiency Virus Vaccine: Correlation Between Genetic Stability and Immunogenicity,” Journal of Virology, Oct. 1997, vol. 71, pp. 7841-7850.
Ramsingh et al., “Severity of Disease Induced by a Pancreatropic Coxsackie B4 Virus Correlates with the H-2Kq Locus of the Major Histocompatibility Complex,” Virus Research, 1989, vol. 14, pp. 347-358.
Caggana et al., “Identification of a Single Amino Acid Residue in the Capsid Protein VP1 of Coxsackievirus B4 That Determines the Virulent Phenotype,” Journal of Virology, Aug. 1993, vol. 67, No. 8, pp. 4797-4803.
Ramsingh et al., “Differential Recruitment of B and T Cells in Coxsackievirus B4-Induced Pancreatitis is Influenced by a Capsid Protein,” Journal of Virology, Nov. 1997, vol. 71, No. 11, pp. 8690-8697.
Ramsingh et al., “Identification of Candidate Sequences that Determine Virulence in Coxsackievirus B4,” Virus Research, 1992, vol. 23, pp. 281-292.
Ramsingh et al., “A Point Mutation in the VP4 Coding Sequence of Coxsackievirus B4 Influences Virulence,” Journal of Virology, Nov. 1995, vol. 69, No. 11, pp. 7278-7281.
Hofling et al., “Expression of an Antigenic Adenovirus Epitope in a Group B Coxsackievirus,” Journal of Virology, May 2000, vol. 74, No. 10, pp. 4570-4578.
M. A. Pallansch, “Coxsackievirus B Epidemiology and Public Health Concerns,” Current Topics Microbiol Immunol, 1997, vol. 223, pp. 13-30.
Rosenberg et al., “Vigorous HIV-1-Specific CD4+ T Cell Responses Associated with Control of Viremia,” Science, Nov. 1997, vol. 278, pp. 1447-1450.
Ramsingh et al., “Coxsackieviruses and Diabetes,” BioEssays, 1997, vol. 19, No. 9, pp. 793-800.
Muckelbauer et al., “The Structure of Coxsackievirus B3 at 3.5 A Resolution,” Structure, Jul. 1995, vol. 3, No. 7, pp. 653-667.
Murphy et al., “Induction by Antigen of Intrathymic Apoptosis of CD4+ CD8+ TCRlo Thymocytes in Vivo,” Science Dec. 1990, vol. 250, pp. 1720-1722.
Ramsingh et al., “T Cells Contribute to Disease Severity During Coxsackievirus B4 Infection,” Journal of Virology, Apr. 1999, vol. 73, No. 4, pp. 3080-3086.
Hunt et al., “Peptides Presented to the Immune System by the Murine Class II Major Histocompatibility Complex Molecule I-Ad,” Science, Jun. 1992, vol. 256, pp. 1817-1820.
Coligan et al., “Chapter 2—Antibody Detection and Preparation,” pp. 2.0.1-2.1.6 and Chapter 3—“In Vitro Assays for Mouse Lymphocyte Function,” pp. 3.0.1-3.12.14,Current Protocols in Immunology. New York: JohnWiley & Sons, 1996.
Janeway et al., “Chapter 4—Antigen Recognition by T Lymphocytes,” pp. 4:1-4:21, Immunobiology: The Immune System in Health and Disease. 3rd ed. London, NewYork: Current Biology Ltd./Garland Publishing Inc., 1997.
Halim et al., “Immunogenicity of a Foreign Peptide Expressed Within a Capsid Protein of an Attenuated Coxsackievirus,” Vaccine, 2001, vol. 19, pp. 958-965.
Chapman et al., “Genetics of Coxsackievirus Virulence,” Current Topics Microbiol Immunol, 1997, vol. 223, pp. 227-258.
Killeen et al., “Regulated Expression of Human CD4 Rescues Helper T Cell Development in Mice Lacking Expression of Endogenous CD4,” EMBO J, 1993, vol. 12, pp. 1547-1553.
Noben-Trauth et al., “Susceptibility to Leishmania Major Infection in Interleukin-4-Deficient Mice,” Science, Feb. 1996, vol. 271, pp. 987-990.
Dalton et al., “Multiple Defects of Immune Cell Function in Mice with Disrupted Interferon-Gamma Genes,” Science, Mar. 1993, vol. 259, pp. 1739-1742.
Henderson et al., “Gag Proteins of the Highly Replicative MN Strain of Human Immunodeficiency Virus Type 1: Posttranslational Modifications, Proteolytic Processings, and Complete Amino Acid Sequences,” Journal of Virology, Apr. 1992, vol. 66, No. 4, pp. 1856-1865.
Page et al., “Construction and Use of a Human Immunodeficiency Virus Vector for Analysis of Virus Infectivity,” Journal of Virology, Nov. 1990, vol. 64, pp. 5270-5276.
Halim et al., “A Therapeutic HIV Vaccine Using Coxsackie-HIV Recombinants: A Possible New Strategy,” Aids Research and Human Retroviruses, 2000, vol. 16, No. 15, pp. 1551-1558.

Affiliated with

Also associated with

Rating

Coxsackievirus B4 expression vectors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Coxsackievirus B4 expression vectors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Coxsackievirus B4 expression vectors and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3800635